Alzamend Neuro

ALZNNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$7.383 M

$1.53 +0.00%

Close of 6 Nov 2026

As of 6 Nov 2026, Alzamend Neuro (ALZN) has a market capitalization of $7.38M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

-$8.77M

Loss-making

Shares outstanding

4,825,723

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 498 →

#428Tempest TherapeuticsTPST$7.51M
#429Theriva BiologicsTOVX$7.43M
#430Alzamend NeuroALZN$7.38M
#431Vistagen TherapeuticsVTGN$7.37M
#432SoligenixSNGX$7.25M

Insiders buying

All insider buying →

2 open-market purchases by officers and directors of Alzamend Neuro, worth $221.9K. Grants and option exercises are excluded.

Milton C. Ault III$111.0K
110,388 shares at $1.01 on 14 Apr 2026 · filed 31 Aug 2026
Milton C. Ault III$111.0K
110,388 shares at $1.01 on 14 Apr 2026 · filed 31 Aug 2026

What if Alzamend Neuro were worth as much as…

Open the what-if tool →

Gold $28.2T

$5,851,325

Per share 3,824,396× higher

Bitcoin $1.53T

$316,605.02

Per share 206,931× higher

Apple $5.02T

$1,039,385

Per share 679,336× higher

Or at a round number

$10.0M $20.0M $50.0M $100.0M

Where these numbers come from

Share counts and financials for Alzamend Neuro are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.